This collection will give you access to recordings to many of the presentations from AMP Europe 2018 and its associated pdf slides (see the topics tab for a complete list of the talks). There is no CME or SAM credit included in this collection.


AMP Europe 2018 in Rotterdam, Netherlands (April 30 - May 2, 2018) showcased the current advances, challenges, and solutions for the advancement of precision cancer medicine. If you missed the meeting or would like to re-watch some of the presentations, this collection is for you. See the "topics" tab for a list of all the available recorded presentations. Click here for more information about the meeting.

Duration:  approximately 9 hrs

 

You can purchase individual sessions or purchase all of AMP Europe 2018: Presentation Recordings for a discount.

  • To purchase the entire series, click the "Add to Cart" button located on the right.
  • To purchase individual talks, click on the "Purchase Individual Topics" button on the right, and select the particular session(s) that you would like to purchase.

If you have questions, please email AMPeducation@amp.org

You may also be interested in:

 

Join the AMP Family for a discount on this item.

All sales are final. No refunds will be issued.

No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.

Course Information
Course Date:
April 30, 2018
Click on a topic name to see details and purchase options.
Monday April 30, 2018

AMP Europe 2018 - Program Book also available here.

Not Available for Individual Purchase

Session Description:

This session focuses on how characterizing and monitoring tumor genomes with biological fluid-base samples could achieve significant improvements in precision medicine. As tumors shed parts of themselves into the circulation, analyses of circulating tumor cells, circulating tumor DNA, and tumor-derived exosomes, often referred to as “liquid biopsies”, may enable tumor genome characterization by minimally invasive means. As data accumulates and test performance continues to improve, exciting applications are on the horizon for faster disease detection, earlier disease diagnosis, and the ability to track disease progression and provide more efficient treatment response. The presenters will bring together the most up-to-date information and the current state-of-the-field for liquid biopsy as well as identify current challenges and solutions.

Session Learning Objectives:

Understand how to apply liquid biopsies for the advancement of precision medicine.

- Evaluate the scope of clinical utility for liquid biopsies in cancer.

- Understand the current challenges and possible solutions for the implantation of liquid biopsy in cancer management.

 

CANCER-ID: European Network for Validation of Liquid Biopsy Tests

- Anna Babayan (Hamburg, Germany)

Personalized Liquid Biopsy: Applications in Colorectal, Bladder, Breast, Lung and Beyond

- C. Jimmy Lin (San Carlos, USA)

 

Duration: 1 hr

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

This session focuses on quality control applications in cancer diagnostics with emphasis on cell free DNA with the emerging need as more and more testing is relying on liquid biopsies. Internal and external quality assurance will be discussed as well the potential need for the availability of reference material that will help in technical and diagnostic standardization.

Session Learning Objectives:

Describe quality measures for cancer diagnostic testing especially using cell free DNA.

- Learn about the existence of reference material, if any, for standardization of analytical testing and control assessment.

- Realize the importance of profi ciency testing in cell free DNA analysis and interpretation.

 

The Role of Reference Materials for Improving Quality of Cancer Diagnostics

- Sandi Deans (Sheffield, UK)

Improving the Profi ciency of Molecular Diagnostics by External Quality Assessment (EQA)

- Michael Neumaier (Heidelberg, Germany)

 

Duration: 1 hr

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Comprehensive Molecular Characterization of Metastatic Cancer Using Whole-Genome Sequencing – a Dutch National Initiative
- Paul Roepman (Amsterdam, The Netherlands)

QIAseq Digital Sequencing and Biomedical Genomics Workbench: Application to Liquid Biopsy in Bladder Cancer
- Francesco Lescai (Aarhus, Denmark) 

* the other two speakers did not provide permission to share the presentation

 

Duration: 30 min

ProductAddPrice
Streaming
AMP Regular Member: $50.00
AMP Technologist Member: $50.00
AMP Associate Member: $50.00
Non-member Price: $100.00
Tuesday May 1, 2018

Session Description:

Currently, molecular diagnostic DNA testing is guiding selection of cancer patients who most likely will benefit from targeted treatment (precision medicine). This selection is largely based on the combination of a specific tumor type and the presence or absence of specific mutations in the DNA. Information present in the transcriptome is largely ignored. In this session the clinical importance of similar DNA alterations in different tumor types as well as the use of a combination of both DNA and transcriptomic analyses for drug response prediction will be addressed.

Session Objectives:

Understand the value of DNA mutation assessment for precision medicine across tumor types.

- Realize the advantages and shortcomings of DNA testing for targeted treatment of cancer.

- Describe how the combination of transcriptome and DNA analysis may improve drug response prediction in cancer patients.

New Insights in the Pathogenesis of MSI Cancers

- Aysel Ahadova (Heidelberg, Germany)

Next Generation Pathology Molecular Diagnostics: Combining DNA and RNA Analysis for Treatment

- Rene Bernards (Amsterdam, The Netherlands)

 

Duration: 1 hr

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

Many challenges exist in assaying mutational burden in cancer (TMB). This interactive session will explore how oncology can best use TMB and what diagnostic information is needed to predict response to immunotherapy.

Session Learning Objective:

Understand and describe the underlying biology and concept of tumor mutational burden (TMB).

- Understand and describe the prerequisites and specifi c characteristics of assays measuring TMB.

- Describe and interpret the clinical utility of TMB.

Microsatellite Instability in Relation to PDL1 Expression and Tumor Mutational Burden in Cancer Patients
- Ari M. VanderWalde, MD, MPH (Germantown, USA)

Novel mRNA Vaccines for Personalized Cancer Immunotherapy

- Alina Klein (Mainz, Germany) - speaker did not provide permission to share the presentation

 

Duration: 1 hr

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Assessment of Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer Treated with Cetuximab Monotherapy
Lindsay Angus (Rotterdam, Netherlands)

External Quality Assessment Schemes for Gene Mutation Testing in Oncology: Comparison of Performance between FFPE-Tissue and ctDNA in Plasma
Kaat Van Casteren (Leuven, Belgium)

Development and Characterization of Multigene Molecular Cytopathology Cell Slides as a Potential Fine Needle Aspirate (FNA)-Mimetic Specimen for Proficiency Testing
Sonika Saddar (Milpitas, USA)

Use of Highly Multiplexed Reference Materials to Facilitate Validation of a Clinical NGS Tumor Fusion RNA Assay
Dan Brudzewsky (Gaithersburg, USA)

Duration: 0.75 hrs

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

This session will explore technologies for Single Cell Sequencing using state-of-the-art NGS techniques and their applications in understanding the function of individual cancer cells by providing a higher resolution of cellular differences and functions in the proper corresponding microenvironment.

Session Learning Objectives:

Identify the variable technologies available for Single Cell Sequencing.

- Compare the sensitivities of the variable techniques employed in Single Cell Sequencing.

- Estimate the importance of Single Cell Sequencing in diagnostic and research applications. 

Simultaneous Analysis of Cancer Clones and Immune Microenvironments Through Single Cell RNA Sequencing
Trevor Pugh, PhD, FACMG (Toronto, Canada)

Duration: 0.75 hrs

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

In 2017, AMP partnered with various stakeholders to develop and publish two related published guideline manuscripts in The Journal for Molecular Diagnostics: 1) Guidelines for Validation of Next Generation Sequencing (NGS)-based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists and 2) Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. This session will be a discussion of how the guidelines were developed and will provide practical case-based implementation advice for laboratories both currently performing somatic NGS and those considering bringing these technologies into their laboratories.

Session Learning Objectives:

Discuss key points of the guideline for validation of NGS-based oncology tests.

- Discuss key points of the guideline for the classifi cation, interpretation, and reporting of somatic sequence variants in NGS-based oncology panels.

- Evaluate utility of these guidelines for development, validation, interpretation and reporting of the laboratory developed NGS tests using clinical case scenarios.

 

Practice Guidelines for Validation, Interpretation and Reporting of NGS-Based Oncology Tests 

Marina N. Nikiforova, MD (Pittsburgh, USA)

Duration: 0.75 hrs.

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00
Wednesday May 2, 2018

Session Description:

This session will provide an update on immunotherapies as well as insights into tumor mutational burden (TMB) and microsatellite instability (MSI) as predictors of response to treatment with checkpoint blockers.

Session Learning Objectives:

Understand the underlying concept and biology of immunooncology (IO) and checkpoint blockade in particular.

- Understand and describe the emerging role of genomic biomarkers predicting IO response.

- Describe and interpret the design and characteristics of assays measuring TMB and MSI.

Immunotherapies in Cancer, 21st Century Vaccines
- Carl Figdor, PhD (Nijmegen, The Netherlands) 

Tumor Mutational Burden-MSI
- Hugo Horlings, MD, PhD (Amsterdam, The Netherlands)

Duration: 1.25 hrs.

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

Several companies’ NGS analysis pipelines will “wrestle” with data fi les that have been provided in advance. The obtained results will be presented consecutively by the companies, after which a general discussion with involvement of participants will take place about the concordant and discrepant results. This session is expected to be both enjoyable and very informative.

Session Learning Objectives:

Appreciate the complexity and diffi culty in NGS data analysis and interpretation.

- Appreciate that there is still no gold standard for NGS data analysis and that most pipelines are to some extent complementary.

- Take into consideration and implement these analysis uncertainties in data reporting for patient care.

Agilent Technologies
- Elias Hage, PhD (Amstelveen, The Netherlands).

Qiagen
- Tim Bonnert, PhD (Manchester, UK)

Thermo Fisher Scientific
- Greg Tyrelle, PhD (The Hague, The Netherlands)

Duration: 1 hr

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00

Session Description:

This session will provide insight into how tomorrow’s healthcare will depend on innovation in data analytics and health informatics

 

Session Learning Objectives:

Describe opportunities for improving patient care using electronic health record databases.

- Identify resources that patient providers may utilize to learn more information about patients similar to their own.

- Discuss how Big Data initiatives can advance biomarker discovery and translational medicine.

 

Turning Little Data into Big Data: Data Science and the Omics

- Mark Hoffman, PhD (Missouri, USA) - Recording not available 

Oncology Research Information Exchange Network (ORIEN)
- William S. Dalton, MD, PhD (Tampa, USA)

ProductAddPrice
Streaming
AMP Regular Member: $99.00
AMP Technologist Member: $99.00
AMP Associate Member: $99.00
Non-member Price: $195.00
Individual topic purchase: Selected
Products
AMP2018 Europe Recordings
AMP Regular Member: $449.00
AMP Technologist Member: $449.00
AMP Associate Member: $449.00
Non-member Price: $649.00